Race Oncology Announces Supply Agreement With Astex Pharmaceuticals for ASTX727 (Oral Decitabine and Cedazuridine) for Extramedullary AML & MDS Trial

The agreement provides ASTX727 (oral decitabine and cedazuridine) for the RAC-006 clinical trial of Zantrene® for the treatment of patients with extramedullary AML and high risk MDS

RAC-006 is the first clinical trial in the world to investigate the targeting of Fatso/Fat mass and obesity associated (FTO) protein as a potential cancer treatment.

The full announcement link is below.

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02504467-2A1365653?access_token=83ff96335c2d45a094df02a206a39ff4

The initial respone seems the market liked the news, was trending sideways all day but jumped 4% once this was released. How does one even value a stock like this, or pretty much most biotechs? RAC is further down the road than many regarding their clinical trials and if their drug is successful then their price will skyrocket. However personally I feel as if playing in this space is a crapshoot (I certainly wish the company every success though even if i'm not involved monetarily).